Target intelligence / Profile preview

Luteolin

Molecular classification
Flavonoid, Flavone, Polyphenol
01

Overview

Luteolin is a naturally occurring flavone found in a wide range of plants, including celery, parsley, broccoli, and various medicinal herbs (PubChem, CID 5280445). It is important to note that Luteolin is a small molecule bioactive compound (a phytochemical) rather than a biological target, such as a receptor, enzyme, or transporter, that therapeutic drugs are typically designed to modulate. Luteolin is widely recognized for its potent antioxidant and anti-inflammatory properties, which it exerts by scavenging reactive oxygen species and inhibiting pro-inflammatory mediators such as COX-2 and NF-κB (NIH, PMC2615542). In oncology research, Luteolin has demonstrated the ability to inhibit tumor growth, suppress angiogenesis, and sensitize cancer cells to traditional chemotherapeutic agents like cisplatin by modulating the PI3K/Akt and MAPK signaling pathways (PubMed, 29653245). While it holds significant therapeutic potential as a lead compound or dietary supplement, its application in clinical settings is currently hindered by its poor pharmacokinetic profile and potential for metabolic interference with other medications.

Other names
3',4',5,7-TetrahydroxyflavoneLuteolineDigitoflavoneCyanidenon 1470
02

Mechanism of action

Luteolin acts as a multi-target bioactive ligand that inhibits various enzymes such as phosphodiesterase 4 (PDE4), cyclooxygenase-2 (COX-2), and various protein kinases, while also modulating key signaling pathways like NF-κB, PI3K/Akt, and MAPK/ERK (NIH, PMC2615542; PubMed, 18992367).

03

Biological functions

Antioxidant activityAnti-inflammatory responseInduction of apoptosisInhibition of cell proliferationInhibition of angiogenesisFree radical scavenging
04

Disease associations

CancerInflammationNeurodegenerative diseaseAllergic rhinitisAsthmaCardiovascular disease
05

Safety considerations

Low oral bioavailabilityInhibition of cytochrome P450 enzymes (e.g., CYP3A4)Potential for significant drug-drug interactionsLack of extensive clinical safety data in humans
06

Interacting drugs

Paclitaxel

4 more in the full profile.

07

Biomarkers

Interleukin-6 (IL-6)Tumor Necrosis Factor-alpha (TNF-α)C-reactive protein (CRP)Caspase-3

Beyond the preview

Go deeper on Luteolin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luteolin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call